DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) will host a quarterly conference call to discuss its third quarter 2014 financial results on Thursday, October 16, 2014, at 7:30 a.m. Central Time.
Beginning in the third quarter 2014, Baxter will be reclassifying and reporting the operating results from its Vaccines Franchise as a discontinued operation for all periods presented. As disclosed in July, Baxter entered into an agreement to sell its commercial vaccines business, including NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis, and FSME-IMMUN, which helps protect against tick-borne encephalitis (TBE), an infection of the brain transmitted by the bite of ticks infected with the TBE-virus. The divestiture is expected to be completed in the fourth quarter of 2014. Concurrent with the sale, the company also committed to a plan to divest R&D programs focused on the development of influenza and Lyme disease vaccines. Historical financial results for the Vaccines Franchise are available on Baxter’s website at www.baxter.com.
Help employers find you! Check out all the jobs and post your resume.
